385 Background: It is well documented that biomarker testing in cancer lags far behind recommended guidelines. To improve testing rates and provide patients access to targeted therapies and clinical trials, a Precision Medicine Quality Initiative (PMQI) was launched across Texas Oncology in July 2022 and is ongoing. The PMQI recommended testing all eligible advanced solid tumor patients utilizing a broad panel next-generation sequencing (NGS) test on somatic tissue or with a liquid biopsy. This study assessed the impact of the initiative on biomarker testing rates and various testing metrics. Methods: This retrospective study analyzed data on biomarker testing during the period of Jan 2022 to Mar 2023. The target population included patients from Texas Oncology (largest private community oncology group in the country) with a diagnosis of advanced “solid tumor” (non-hematologic malignancy). Per PMQI, biomarker testing was ordered through Trapelo (online clinical decision support tool) or Precision Medicine Team. The order was tracked through IknowMed (EMR system) and CareEvolve (provider facing, customized database tracking orders/results real-time). This study analyzed data in Ca
📖 افتح في inklap 🔗 DOI 📮 اطلب بحثاً